Leaflet: information for the user
Escarpilo 1.200 mg tablets
eslicarbazepine, acetate
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
This medication contains the active ingredient eslicarbazepine acetate.
This medication belongs to a group of medications called antiepileptics, used to treat epilepsy, a disease where the affected person has seizures or repeated convulsive crises.
This medication is used:
Your doctor has prescribed this medication to reduce the number of seizures.
Do not take Escarpilo:
Consult your doctor or pharmacist before starting this medication.
Inform your doctor immediately:
Inform your doctor:
A small number of people taking antiepileptic medications have had thoughts of self-harm or suicide. If this occurs while taking this medication, contact your doctor immediately.
This medication may cause dizziness and/or disorientation, particularly at the start of treatment. Be extra cautious while taking this medication to avoid accidental injuries, such as falls.
Be extra cautious with this medication
In the post-marketing experience, severe skin reactions that may be life-threatening, including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported in patients treated with this medication.
If you develop a severe rash or other skin symptoms (see section 4), stop taking this medication and consult your doctor or seek medical attention immediately.
In patients of Thai and Chinese Han ethnic origin, the risk of severe skin reactions associated with carbamazepine or chemically related compounds may be predicted by blood analysis of these patients. Your doctor will advise on the need for this blood test before taking this medication.
Children
This medication should not be administered to children under 6 years of age.
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. This is to ensure that none of them interfere with the way this medication works, or that this medication interferes with the effect of such medications. Inform your doctor if you are taking:
See the section “Pregnancy and Breastfeeding” for recommendations on contraception.
This medication is not recommended during pregnancy, as the effects of this medication on pregnancy and the fetus are unknown.
If you plan to become pregnant, discuss this with your doctor before stopping your contraceptive method and before becoming pregnant. Your doctor may decide to change your treatment.
There is limited data on the use of eslicarbazepine acetate in pregnant women. Research has shown an increased risk of congenital defects and neurological development problems (brain development) in children of women taking antiepileptic medications, particularly when taking more than one antiepileptic medication at a time.
If you are or think you may be pregnant, inform your doctor immediately. Do not stop taking your medication until you have discussed it with your doctor. Stopping your medication without consulting your doctor may cause seizures, which can be hazardous to you and your unborn child. Your doctor may decide to change your treatment.
If you are a fertile woman and do not plan to become pregnant, use an effective contraceptive method during treatment with Escarpilo.
This medication may affect the effectiveness of hormonal contraceptives, such as the birth control pill, and make them less effective in preventing pregnancy.
Therefore, it is recommended to use other safe and effective contraceptive methods while taking Escarpilo.
Discuss this with your doctor, who will advise on the most suitable contraceptive method for you while taking this medication. If you stop taking this medication, continue using an effective contraceptive method until the end of the current menstrual cycle.
If you take Escarpilo during pregnancy, your baby may also be at risk of bleeding problems immediately after birth. Your doctor may give you and your baby a medication to prevent this.
Do not breastfeed while taking this medication. It is unknown whether it passes into breast milk.
Driving and Operating Machinery
This medication may cause dizziness, disorientation, and affect your vision, particularly at the start of treatment. If this occurs, do not drive or operate any tools or machinery.
This medication contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Initial treatment dose
400 mg once a day for one or two weeks, before increasing to the maintenance dose. Your doctor will decide if you should take this dose for one or two weeks.
Maintenance dose
The usual maintenance dose is 800 mg once a day.
Depending on how you respond to this medication, the dose may be increased to 1,200 mg once a day. If you are taking eslicarbazepine alone (monotherapy), your doctor may consider increasing your dose to 1,600 mg once a day.
If you have kidney problems, you will usually be given a lower dose of this medication. Your doctor will determine the correct dose for you. This medication is not recommended if you have severe kidney problems.
If you are an older person and taking this medication in monotherapy, the dose of 1,600 mg is not suitable for you.
Initial treatment dose
The initial dose is 10 mg per kg of body weight once a day for one or two weeks, before increasing to the maintenance dose.
Maintenance dose
Depending on your response to this medication, the dose may be increased by 10 mg per kg of body weight, at intervals of one or two weeks, up to 30 mg per kg of body weight. The maximum dose is 1,200 mg once a day.
Children with a body weight of 60 kg or more should take the same dose as adults.
This medication is administered orally. Swallow the tablet with a glass of water. This medication can be taken with or without food.
If you have difficulty swallowing the tablet whole, you can crush it and mix it with water or apple sauce, and take it immediately.
The tablet can be divided into equal doses.
If you accidentally take more Escarpilo than you should, you are at risk of having more seizures; or you may feel that your heart is beating irregularly or faster. Contact your doctor or go immediately to a hospital if you experience any of these symptoms. Bring the medication packaging with you, so the doctor knows what you have taken.
You can also call the Toxicology Information Service, Tf: 915620420, indicating the medication and the amount ingested.
If you forget to take Escarpilo
If you forget to take a tablet, take it as soon as you remember and continue as usual. Do not take a double dose to make up for the missed doses.
Do not suddenly stop taking the tablets. If you do, you are at risk of having more seizures. Your doctor will decide for how long you should take this medication. If your doctor decides to stop your treatment with this medication, they will usually reduce your dose gradually. It is essential that you complete the treatment as instructed by your doctor; otherwise, your symptoms may worsen.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
The following side effects can be very serious. If they occur, stop taking this medicine and inform your doctor or go to the hospital immediately, as you may need urgent medical treatment:
The very common side effects (can affect more than 1 in 10 people) are:
•dizziness or drowsiness
The common side effects (can affect up to 1 in 10 people) are:
• feeling unsteady, or like you are spinning or floating
The side effects that are infrequent (can affect up to 1 in 100 people) are:
The side effects of unknown frequency (cannot be estimated from available data) are:
The use of eslicarbazepine is associated with an ECG anomaly called an increase in the PR interval. Side effects associated with this ECG anomaly may occur (such as fainting and slowing of heartbeats).
There have been reports of bone disorders, including osteopenia and osteoporosis (bone thinning) and fractures with antiepileptic drugs related structurally to carbamazepine and oxcarbazepine. Talk to your doctor or pharmacist if you are on long-term treatment with antiepileptics, have a history of osteoporosis, or take steroids.
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in the Spanish System of Pharmacovigilance of Medicines for Human Use: www.notificaRAM.es..By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack, bottle, and box after the letters CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through drains or trash. Dispose of packaging and medications you no longer need at the SIGRE point of your pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Appearance of the product and contents of the packaging
Escarpilo 1.200 mg tablets are white to off-white, oblong, biconvex (23 x 10 mm), scored on one side.
The tablet can be divided into equal doses.
The tablets are packaged in blisters, in carton boxes containing 28 or 30 tablets.
Only some packaging sizes may be marketed.
Neuraxpharm Spain, S.L.U.
Avda. Barcelona, 69
08970 – Sant Joan Despí
Barcelona – Spain
Responsible for manufacturing
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona, 69
08970 Sant Joan Despí
Barcelona - Spain
or
Neuraxpharm Arzneimittel GmbH
Elisabeth-Selbert-Strasse 23
40764 Langenfeld
Germany
This medicine is authorized in the Member States of the European Economic Area with the following names:
Portugal: Escarpilo
Spain: Escarpilo 1.200 mg tablets
December 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es .
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.